RU2019124473A - Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани - Google Patents
Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани Download PDFInfo
- Publication number
- RU2019124473A RU2019124473A RU2019124473A RU2019124473A RU2019124473A RU 2019124473 A RU2019124473 A RU 2019124473A RU 2019124473 A RU2019124473 A RU 2019124473A RU 2019124473 A RU2019124473 A RU 2019124473A RU 2019124473 A RU2019124473 A RU 2019124473A
- Authority
- RU
- Russia
- Prior art keywords
- aav
- particle
- raav
- specified
- paragraphs
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 22
- 210000000056 organ Anatomy 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000002245 particle Substances 0.000 claims 26
- 241000702421 Dependoparvovirus Species 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 241000124008 Mammalia Species 0.000 claims 15
- 210000000234 capsid Anatomy 0.000 claims 11
- 102000004190 Enzymes Human genes 0.000 claims 10
- 108090000790 Enzymes Proteins 0.000 claims 10
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003623 enhancer Substances 0.000 claims 6
- 210000004185 liver Anatomy 0.000 claims 6
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 3
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 3
- 230000001276 controlling effect Effects 0.000 claims 3
- 201000004502 glycogen storage disease II Diseases 0.000 claims 3
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 1
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 1
- 101710197658 Capsid protein VP1 Proteins 0.000 claims 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 1
- 208000033868 Lysosomal disease Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003890 endocrine cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000002894 multi-fate stem cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000004853 protein function Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002955 secretory cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002627 tracheal intubation Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (45)
1. Рекомбинантная частица AAV (rAAV), содержащая последовательность капсида AAV SEQ ID NO:5, где геном указанной частицы rAAV содержит инвертированный концевой повтор AAV (ITR) и гетерологичную полинуклеотидную последовательность, которая кодирует фермент, участвующий в развитии лизосомной болезни накопления, где указанный полинуклеотид функционально связан с элементом, контролирующим экспрессию.
2. Частица rAAV по п. 1, где указанный элемент, контролирующий экспрессию, включает конститутивный или регуляторный контролирующий элемент.
3. Частица rAAV по п. 1, где указанный элемент, контролирующий экспрессию, включает тканесецифический элемент, контролирующий экспрессию, или промотор.
4. Частица rAAV по п. 3, где указанный тканесецифический элемент, контролирующий экспрессию, или промотор является специфическим по отношению к печени.
5. Частица rAAV по п. 1, где указанный элемент, контролирующий экспрессию, включает печень-специфический энхансер и промотор.
6. Частица rAAV по п. 1, где указанный элемент, контролирующий экспрессию, представляет собой ApoE-hAAT энхансер-промотор.
7. Частица rAAV по любому из пп. 1-6, где указанная гетерологичная полинуклеотидная последовательность связана с поли-A последовательностью.
8. Частица rAAV по любому из пп. 1-7, где указанная гетерологичная полинуклеотидная последовательность фланкирована 5' и 3'нетранслированными областями.
9. Частица rAAV по любому из пп. 1-8, где указанная гетерологичная полинуклеотидная последовательность фланкирована 5' и/или 3' AAV ITR.
10. Частица rAAV по любому из пп. 1-9, где указанная AAV ITR происходит из AAV2.
11. Частица rAAV по любому из пп. 1-10, где указанная частица rAAV имеет повышенный топизм к гепатоцитам по сравнению с Rh74, AAV2 или AAV8 серотипам.
12. Рекомбинантная частица AAV (rAAV), содержащая капсидный белок VP1, имеющий аминокислотную последовательность SEQ ID NO:5, где геном указанной частицы rAAV содержит в 5'-3' направлении:
первый инвертированный концевой повтор AAV (ITR),
печень-специфический энхансер и промотор,
полинуклеотидную последовательность, которая кодирует фермент, участвующий в развитии лизосомной болезни накопления, функционально связанную с печень-специфическиим энхансером и промотором,
поли-A последовательность; и
вторую AAV ITR.
13. Частица rAAV по п. 14, где указанная первая и вторая AAV ITR происходят из AAV2.
14. Частица rAAV по п.14 или 15, где указанные печень-специфические энхансер и промотор представляют собой ApoE-hAAT энхансер-промотор.
15. Частица rAAV по любому из пп. 12-14, где указанная полинуклеотидная последовательность фланкирована 5' и 3' нетранслированными областями.
16. Фармацевтическая композиция, содержащая указанную частицу rAAV по любому из пп. 1-15.
17. Фармацевтическая композиция, содержащая указанную частицу rAAV по любому из пп. 1-15 и фармацевтически приемлемый носитель.
18. Фармацевтическая композиция по п. 16 или 17, где указанная фармацевтическая композиция дополнительно содержит пустой капсид AAV.
19. Фармацевтическая композиция по п.16 или 17, где указанная фармацевтическая композиция дополнительно содержит пустой капсид AAV-Rh74 или пустой капсид, содержащий последовательность капсида AAV SEQ ID NO:5.
20. Способ получения частицы rAAV по любому из пп. 1-15, включающий культивирование хелперной клетки, содержащей рекомбинантную плазмиду, содержащую геном частицы rAAV по любому из пп. 1-15.
21. Способ лечения млекопитающего, нуждающегося в лечении болезни Помпе, включающий введение указанному субъекту терапевтически эффективного количества фармацевтической композиции по любому из пп. 16-19.
22. Способ доставки или переноса гетерологичной полинуклеотидной последовательности млекопитающему, включающий введение указанному млекопитающему рекомбинантной частицы AAV (rAAV), содержащей рекомбинантный векторный геном, содержащий гетерологичную полинуклеотидную последовательность, где гетерологичная полинуклеотидная последовательность кодирует фермент, участвующий в развитии лизосомной болезни накопления, таким образом доставляя или перенося гетерологичную полинуклеотидную последовательность млекопитающему, где рекомбинантная частица AAV содержит последовательность капсида AAV, указанную в п. 1.
23. Способ по п. 22, где указанная гетерологичная полинуклеотидная последовательность функционально связана с элементом, контролирующим экспрессию, предоставляющую транскрипцию указанной гетерологичной полинуклеотидной последовательности.
24. Способ лечения млекопитающего с дефицитом фермента, участвующего в развитии лизосомной болезни накопления, включающий: (a) предоставление рекомбинантной частицы AAV (rAAV), содержащей последовательность AAV капсида SEQ ID NO:5, где векторный геном содержит гетерологичную полинуклеотидную последовательность, кодирующую фермент, который может корректировать недостаточную экспрессию или функцию белка, где гетерологичная полинуклеотидная последовательность функционально связана с элементом, контролирующим экспрессию, предоставляющую транскрипцию указанной гетерологичной полинуклеотидной последовательности; и (b) введение количества рекомбинантной частицы AAV в млекопитающее, где указанный фермент экспрессируется у млеуопитающего.
25. Способ по п. 22 или 24, где указанная гетерологичная полинуклеотидная последовательность или указанный фермент, участвующего в развитии лизосомной болезни накопления, экспрессируется в количестве, имеющим терапевтический эффект на млекопитающее.
26. Способ по п. 22 или 24, где указанной лизосомной болезнью является болезнь Помпе.
27. Способ по п. 22 или 24, где указанное млекопитающее страдает от болезни Помпе.
28. Способ по п. 22 или 24, где фермент, участвующего в развитии лизосомной болезни накопления, экспрессируется в клетке, ткани или органе указанного млекопитающего.
29. Способ по п. 28, где указанная клетка включает секреторную клетку.
30. Способ по п. 28, где указанная клетка включает эндокринную клетку.
31. Способ по п. 28, где указанная клетка включает гепатоцит, эпителиальную клетку или тотипотетную, плюрипотентную или мультипотентную стволовую клетку.
32. Способ по п. 28, где указанная ткань или орган указанного млекопитающего включает печень.
33. Способ по любому из пп. 21-32, где указанное млекопитающее продуцирует недостаточное количество фермента, участвующего в развитии лизосомной болезни накопления, или дефектный или аберрантный фермент, участвующий в развитии лизосомной болезни накопления.
34. Способ по любому из пп. 21-33, где указанный вектор AAV доставляют внутривенно, внутриартериальное, внутримышечное, подкожно, путем интубации, через катетер, или внутрь полости.
35. Способ по любому из пп. 21-34, где указанное млекопитающее представляет собой человека.
36. Способ по любому из пп. 21-35, где указанное млекопитающее является сероположительными по AAV серотипу иному, чем AAV-Rh74.
37. Способ по любому из пп. 21-36, где указанное млекопитающее является сероположительными по AAV серотипу AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 или AAV11.
38. Способ по любому из пп. 21-35, где указанное млекопитающее является сероотрицательным или сероположительными по AAV-Rh74.
39. Способ по любому из пп. 21-38, дополнительно включающий введение пустого капсида AAV.
40. Способ по любому из пп. 21-39, дополнительно включающий введение пустого капсида AAV-Rh74 или пустого капсида, содержащего последовательность капсида AAV SEQ ID NO:5.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361857161P | 2013-07-22 | 2013-07-22 | |
US61/857,161 | 2013-07-22 | ||
US201461985365P | 2014-04-28 | 2014-04-28 | |
US61/985,365 | 2014-04-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016105965A Division RU2697444C2 (ru) | 2013-07-22 | 2014-07-22 | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2019124473A true RU2019124473A (ru) | 2019-11-11 |
Family
ID=52343737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019124473A RU2019124473A (ru) | 2013-07-22 | 2014-07-22 | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани |
RU2016105965A RU2697444C2 (ru) | 2013-07-22 | 2014-07-22 | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016105965A RU2697444C2 (ru) | 2013-07-22 | 2014-07-22 | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани |
Country Status (25)
Country | Link |
---|---|
US (2) | US9840719B2 (ru) |
EP (2) | EP3613440A1 (ru) |
JP (3) | JP6495273B2 (ru) |
KR (3) | KR102380265B1 (ru) |
CN (2) | CN105579465B (ru) |
AU (4) | AU2014293253B2 (ru) |
CA (2) | CA2919103C (ru) |
DK (1) | DK3024498T3 (ru) |
ES (1) | ES2774966T3 (ru) |
HK (1) | HK1223849A1 (ru) |
HU (1) | HUE047996T2 (ru) |
IL (5) | IL297919A (ru) |
MX (2) | MX2016001044A (ru) |
MY (1) | MY175477A (ru) |
NZ (1) | NZ716102A (ru) |
PE (1) | PE20160188A1 (ru) |
PH (2) | PH12016500162A1 (ru) |
PL (1) | PL3024498T3 (ru) |
PT (1) | PT3024498T (ru) |
RU (2) | RU2019124473A (ru) |
SA (1) | SA516370442B1 (ru) |
SG (2) | SG10201809075XA (ru) |
SI (1) | SI3024498T1 (ru) |
WO (1) | WO2015013313A2 (ru) |
ZA (1) | ZA201600481B (ru) |
Families Citing this family (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2359865B1 (en) | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
PT3024498T (pt) * | 2013-07-22 | 2020-03-06 | Childrens Hospital Philadelphia | Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos |
FI3851537T3 (fi) | 2014-04-25 | 2024-03-21 | Genethon | Hyperbilirubinemian hoito |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
BR112017009497A2 (pt) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | polinucleotídeos de aadc para o tratamento da doença de parkinson |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
US11103597B2 (en) * | 2015-05-14 | 2021-08-31 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers outside ITR |
IL309741A (en) | 2015-06-23 | 2024-02-01 | Childrens Hospital Philadelphia | Modified factor IX, and preparations, methods and uses for gene transfer to cells, organs and tissues |
IL257628B2 (en) | 2015-09-28 | 2023-04-01 | Univ North Carolina Chapel Hill | Methods and compositions for stealth virus antibody vectors |
PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
KR102200642B1 (ko) | 2015-11-05 | 2021-01-12 | 뱀부 테라퓨틱스 인코포레이티드 | 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터 |
PE20181534A1 (es) * | 2015-12-01 | 2018-09-26 | Spark Therapeutics Inc | Metodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension sin suero adecuado para uso clinico |
EP3384034B1 (en) | 2015-12-02 | 2020-07-08 | The Board of Trustees of the Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
CA3006569A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
WO2017106326A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
CA3007330A1 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Composition for treatment of crigler-najjar syndrome |
WO2017143100A1 (en) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
JP2019509748A (ja) * | 2016-03-30 | 2019-04-11 | スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. | 組換えタンパク質及び/又はウイルスベクター製造のための細胞株 |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
PE20190401A1 (es) * | 2016-07-26 | 2019-03-13 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
EP3293260A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
KR20240001721A (ko) | 2016-09-12 | 2024-01-03 | 제네똥 | 산-알파 글루코시다제 변이체 및 이의 용도 |
EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
MX2019005266A (es) * | 2016-11-04 | 2019-09-27 | The Children´S Hospital Of Philadelphia | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. |
JP7215716B2 (ja) | 2017-01-13 | 2023-01-31 | 学校法人自治医科大学 | 肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのaavベクター |
US11541131B2 (en) | 2017-03-10 | 2023-01-03 | Genethon | Treatment of glycogen storage disease III |
US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
JP7132934B2 (ja) * | 2017-03-15 | 2022-09-07 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法 |
CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
US20200172927A1 (en) * | 2017-05-15 | 2020-06-04 | The Trustees Of Columbia University In The City Of New York | Reprogramming metabolism by inhibiting vhl for treatment of neurodegeneration |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
BR112020000995A2 (pt) * | 2017-07-17 | 2020-09-08 | Spark Therapeutics, Inc. | métodos e usos de aférese |
CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
US20190085358A1 (en) * | 2017-08-25 | 2019-03-21 | Ovid Therapeutics Inc. | Recombinant adeno-associated vectors |
TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP2021511020A (ja) | 2018-01-17 | 2021-05-06 | アドリーナス セラピューティクス, インコーポレイテッド | 21−ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
US20210346519A1 (en) | 2018-02-07 | 2021-11-11 | Genethon | Hybrid regulatory elements |
JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
WO2019168961A1 (en) * | 2018-02-27 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
SG11202008687XA (en) * | 2018-03-16 | 2020-10-29 | Res Inst Nationwide Childrens Hospital | Increasing tissue specific gene delivery by capsid modification |
JP7378417B2 (ja) | 2018-03-30 | 2023-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 増強されたヒト膵臓トロピズムを有する新規な組換えアデノ随伴ウイルスキャプシド |
JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
AU2019247746B2 (en) | 2018-04-03 | 2024-08-15 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
TN2020000187A1 (en) | 2018-04-05 | 2022-04-04 | Univ Devry Val Dessonne | Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism |
WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
EP3784697A4 (en) * | 2018-04-27 | 2022-07-06 | Spark Therapeutics, Inc. | GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE |
WO2019212922A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
CA3098565A1 (en) | 2018-04-29 | 2019-11-07 | Claire G. ZHANG | Scalable clarification process for recombinant aav production |
CN117535247A (zh) * | 2018-05-07 | 2024-02-09 | 北卡罗来纳-查佩尔山大学 | 合理的多倍体腺相关病毒载体及其制造和使用方法 |
TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
CN112469822A (zh) | 2018-06-14 | 2021-03-09 | 再生生物股份有限公司 | 用于重组aav生产的阴离子交换色谱 |
DK3833746T5 (da) | 2018-08-08 | 2024-08-19 | Genethon | Mini-gde til behandlingen af glykogenlagringssygdom iii |
JP2021533757A (ja) | 2018-08-10 | 2021-12-09 | リジェネクスバイオ インコーポレイテッド | 組換えaav生成のためのスケーラブルな方法 |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
AU2019362833A1 (en) | 2018-10-15 | 2021-04-29 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
CN112888426A (zh) * | 2018-10-25 | 2021-06-01 | 百特奥尔塔公司 | Aav三质粒系统 |
CA3120087A1 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence |
CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
AU2020248116A1 (en) * | 2019-03-28 | 2021-10-14 | President And Fellows Of Harvard College | Engineered adeno-associated (AAV) vectors for transgene expression |
TW202102526A (zh) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
US20220275358A1 (en) | 2019-04-11 | 2022-09-01 | Regenxbio Inc. | Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions |
US20220143115A1 (en) | 2019-04-19 | 2022-05-12 | Regenxbio Inc. | Adeno-Associated Virus Vector Formulations and Methods |
BR112021020888A2 (pt) | 2019-04-19 | 2021-12-21 | Genethon | Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23 |
TW202106708A (zh) | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
US20220233715A1 (en) * | 2019-05-08 | 2022-07-28 | Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences | Aav mutant that efficiently infects supporting cells |
CN110205297A (zh) * | 2019-05-15 | 2019-09-06 | 华北理工大学 | 一种重组脂肪干细胞及其重组方法 |
EP3990030A1 (en) | 2019-06-27 | 2022-05-04 | Pfizer Inc. | Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy |
EP3996696A1 (en) | 2019-07-09 | 2022-05-18 | Genethon | Treatment of glycogen storage disease (gsd) |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
EP4006160A4 (en) | 2019-07-12 | 2023-06-28 | Gene Therapy Research Institution Co., Ltd. | Adeno-associated virus virion for gene transfer to human liver |
WO2021021661A1 (en) | 2019-07-26 | 2021-02-04 | Regenxbio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
RU2751592C2 (ru) * | 2019-08-22 | 2021-07-15 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |
WO2021050666A1 (en) * | 2019-09-11 | 2021-03-18 | Aav Gene Therapeutics, Inc. | Aav-zyme and use for infusion replacement therapy |
TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療c型尼曼—匹克病之腺相關病毒載體 |
WO2021078834A1 (en) | 2019-10-22 | 2021-04-29 | Genethon | Chimeric acid-alpha glucosidase polypeptides and uses thereof |
WO2021078833A1 (en) | 2019-10-22 | 2021-04-29 | Genethon | Chimeric polypeptides and uses thereof |
MX2022005869A (es) * | 2019-11-14 | 2022-06-14 | Biomarin Pharm Inc | Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado. |
US20230016983A1 (en) | 2019-11-19 | 2023-01-19 | lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) | Antisense oligonucleotides and thier use for the treatment of cancer |
KR20220107222A (ko) | 2019-11-28 | 2022-08-02 | 리젠엑스바이오 인크. | 마이크로디스트로핀 유전자 치료 작제물 및 이의 용도 |
US20230032826A1 (en) | 2019-12-18 | 2023-02-02 | Genethon | Production of recombinant viral vectors from plant hairy roots |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
BR112022015036A2 (pt) | 2020-01-29 | 2022-10-11 | Regenxbio Inc | Vírus adenoassociado recombinante (raav), composição farmacêutica, polinucleotídeo, plasmídeo de raav, célula ex vivo, método de produção de um raav, método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo iva (mps iva) |
EP3892720A1 (en) | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
WO2021229255A1 (en) | 2020-05-14 | 2021-11-18 | Genethon | Tools and method for preventing a a¥ neutralization by antibodies |
EP3913060A1 (en) | 2020-05-22 | 2021-11-24 | Genethon | Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy |
AU2021305665A1 (en) | 2020-07-10 | 2023-02-23 | Centre National De La Recherche Scientifique | Methods and compositions for treating epilepsy |
WO2022043280A1 (en) | 2020-08-24 | 2022-03-03 | Genethon | C-terminal truncated gde for the treatment of glycogen storage disease iii |
EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
JP2023545722A (ja) | 2020-10-07 | 2023-10-31 | リジェネックスバイオ インコーポレイテッド | 遺伝子治療剤の眼送達のためのアデノ随伴ウイルス |
US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
WO2022079083A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffmann-La Roche Ag | Nucleic acid constructs for va rna transcription |
AU2021363098A1 (en) | 2020-10-15 | 2023-05-18 | F. Hoffmann-La Roche Ag | Nucleic acid constructs for simultaneous gene activation |
CN116528892A (zh) | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
WO2022094255A2 (en) | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
IL302282A (en) | 2020-10-29 | 2023-06-01 | Regenxbio Inc | Vectored TNF-alpha antagonists for ocular indications |
MX2023005218A (es) | 2020-11-03 | 2023-05-16 | Pfizer | Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico. |
CN116917471A (zh) | 2020-12-09 | 2023-10-20 | 吉尼松公司 | 溶酶体酸性脂肪酶变体及其用途 |
WO2022130172A1 (en) | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins |
AU2021403076A1 (en) | 2020-12-16 | 2023-06-29 | Regenxbio Inc. | Method of producing a recombinant adeno-associated virus particle |
AU2021404944A1 (en) | 2020-12-23 | 2023-07-06 | Pfizer Inc. | Methods for purification of aav vectors by affinity chromatography |
EP4271479A1 (en) | 2020-12-29 | 2023-11-08 | RegenxBio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
KR20230133314A (ko) | 2021-01-21 | 2023-09-19 | 리젠엑스바이오 인크. | 재조합 폴리펩티드 및 바이러스의 개선된 생산 |
AR125143A1 (es) | 2021-03-19 | 2023-06-14 | Adrenas Therapeutics Inc | Terapias génicas para la deficiencia de la 21-hidroxilasa |
WO2022208342A1 (en) | 2021-04-01 | 2022-10-06 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
US20240189447A1 (en) * | 2021-04-16 | 2024-06-13 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
IL307902A (en) | 2021-04-26 | 2023-12-01 | Regenxbio Inc | Administering microdystrophin gene therapy to treat dystrophinopathy |
JP2024515902A (ja) | 2021-04-26 | 2024-04-10 | アレクシオン ファーマ インターナショナル オペレーションズ リミテッド | 組織向性が改善されたアデノ随伴ウイルスベクターカプシド |
US20240218397A1 (en) | 2021-05-04 | 2024-07-04 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
EP4337267A1 (en) | 2021-05-11 | 2024-03-20 | RegenxBio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
WO2022269466A1 (en) | 2021-06-22 | 2022-12-29 | Pfizer Inc. | Production of adeno-associated virus vector in insect cells |
CA3226452A1 (en) | 2021-07-19 | 2023-01-26 | New York University | Auf1 combination therapies for treatment of muscle degenerative disease |
AR126839A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
AR126840A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta |
WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
EP4413018A1 (en) | 2021-10-07 | 2024-08-14 | RegenxBio Inc. | Recombinant adeno-associated viruses for targeted delivery |
WO2023060272A2 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
IL311871A (en) * | 2021-10-08 | 2024-06-01 | Dyno Therapeutics Inc | Capsid variants and methods of using them |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
EP4423285A1 (en) | 2021-10-28 | 2024-09-04 | RegenxBio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
CA3236365A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
WO2023114816A1 (en) | 2021-12-14 | 2023-06-22 | Neurogene, Inc. | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
EP4215245A1 (en) | 2022-01-19 | 2023-07-26 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment |
AU2023208274A1 (en) | 2022-01-21 | 2024-08-01 | AstraZeneca Ireland Limited | Gene therapy for gaucher disease |
GB202201242D0 (en) | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
TW202346590A (zh) | 2022-03-13 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 經修飾之肌肉特異性啟動子 |
WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
WO2023198685A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Method for determining aav genomes |
WO2023201277A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
WO2023201308A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Gene therapy for treating an ocular disease |
GB202206336D0 (en) | 2022-04-29 | 2022-06-15 | Univ Edinburgh | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders |
TW202417633A (zh) | 2022-05-03 | 2024-05-01 | 美商銳進科斯生物股份有限公司 | 用於眼適應症之載體化抗TNF-α抑制劑 |
WO2023215806A2 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
WO2023227438A1 (en) | 2022-05-23 | 2023-11-30 | F. Hoffmann-La Roche Ag | Raman-based method for the differentiation of aav particle serotype and aav particle loading status |
WO2023232922A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
WO2023237731A1 (en) | 2022-06-09 | 2023-12-14 | Genethon | N-terminal truncated gde for the treatment of glycogen storage disease iii |
WO2024003687A1 (en) | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
WO2024013239A1 (en) | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
WO2024038002A1 (en) | 2022-08-15 | 2024-02-22 | F. Hoffmann-La Roche Ag | Prevention or mitigation of adverse effects related to recombinant viral vectors |
WO2024038365A1 (en) | 2022-08-16 | 2024-02-22 | Pfizer Inc. | Methods for purification of aav vectors by anion exchange chromatography |
WO2024044725A2 (en) | 2022-08-24 | 2024-02-29 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
WO2024056561A1 (en) | 2022-09-12 | 2024-03-21 | F. Hoffmann-La Roche Ag | Method for separating full and empty aav particles |
WO2024081746A2 (en) | 2022-10-11 | 2024-04-18 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
WO2024146935A1 (en) | 2023-01-06 | 2024-07-11 | Institut National de la Santé et de la Recherche Médicale | Intravenous administration of antisense oligonucleotides for the treatment of pain |
WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
WO2024165456A1 (en) | 2023-02-07 | 2024-08-15 | F. Hoffmann-La Roche Ag | Method for the detection of anti-aav particle antibodies |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1202962A (en) | 1982-10-19 | 1986-04-08 | David P. Clifford | Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
AU1775901A (en) * | 1999-11-17 | 2001-05-30 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US20080220015A1 (en) | 2001-08-03 | 2008-09-11 | Nokad, S.A. | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins |
NZ618298A (en) | 2001-11-13 | 2015-04-24 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
CA2469785C (en) * | 2001-12-17 | 2014-04-22 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
US20040028654A1 (en) | 2002-03-22 | 2004-02-12 | Board Of Regents, The University Of Texas System | Protamine-adenoviral vector complexes and methods of use |
CA2483624A1 (en) | 2002-05-01 | 2004-04-01 | University Of Florida Research Foundation, Inc. | Improved raav expression systems for genetic modification of specific capsid proteins |
HUE034785T2 (en) * | 2003-06-19 | 2018-02-28 | Genzyme Corp | Reduced immunoreactivity of AAV virions and their use |
CA2580189C (en) | 2004-09-29 | 2013-05-21 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
EP2359865B1 (en) * | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
WO2008027084A2 (en) | 2006-04-28 | 2008-03-06 | The Trustees Of The University Of Pennsylvania | Modified aav vectors having reduced capsid immunogenicity and use thereof |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
EP2561067B1 (en) | 2010-04-23 | 2018-11-14 | University of Florida Research Foundation, Inc. | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) |
ES2698203T3 (es) | 2010-04-23 | 2019-02-01 | Univ Massachusetts | Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos |
US8609088B2 (en) * | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
US20130039888A1 (en) * | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
EP2782596A4 (en) | 2011-11-22 | 2015-07-29 | Philadelphia Children Hospital | VIRAL VECTORS FOR HIGHLY EFFECTIVE TRANSGEN DELIVERY |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
KR102057540B1 (ko) * | 2012-02-17 | 2019-12-19 | 더 칠드런스 호스피탈 오브 필라델피아 | 세포, 기관 및 조직으로의 유전자 전이를 위한 aav 벡터 조성물 및 방법 |
JP6342886B2 (ja) * | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
PT3024498T (pt) * | 2013-07-22 | 2020-03-06 | Childrens Hospital Philadelphia | Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos |
IL309741A (en) | 2015-06-23 | 2024-02-01 | Childrens Hospital Philadelphia | Modified factor IX, and preparations, methods and uses for gene transfer to cells, organs and tissues |
-
2014
- 2014-07-22 PT PT148297799T patent/PT3024498T/pt unknown
- 2014-07-22 SG SG10201809075XA patent/SG10201809075XA/en unknown
- 2014-07-22 PE PE2016000095A patent/PE20160188A1/es unknown
- 2014-07-22 KR KR1020167004456A patent/KR102380265B1/ko active IP Right Grant
- 2014-07-22 RU RU2019124473A patent/RU2019124473A/ru unknown
- 2014-07-22 MX MX2016001044A patent/MX2016001044A/es unknown
- 2014-07-22 ES ES14829779T patent/ES2774966T3/es active Active
- 2014-07-22 SI SI201431511T patent/SI3024498T1/sl unknown
- 2014-07-22 CA CA2919103A patent/CA2919103C/en active Active
- 2014-07-22 CN CN201480048028.0A patent/CN105579465B/zh active Active
- 2014-07-22 CA CA3209883A patent/CA3209883A1/en active Pending
- 2014-07-22 RU RU2016105965A patent/RU2697444C2/ru active
- 2014-07-22 EP EP19197005.2A patent/EP3613440A1/en active Pending
- 2014-07-22 DK DK14829779.9T patent/DK3024498T3/da active
- 2014-07-22 AU AU2014293253A patent/AU2014293253B2/en active Active
- 2014-07-22 PL PL14829779T patent/PL3024498T3/pl unknown
- 2014-07-22 JP JP2016529835A patent/JP6495273B2/ja active Active
- 2014-07-22 NZ NZ716102A patent/NZ716102A/en unknown
- 2014-07-22 IL IL297919A patent/IL297919A/en unknown
- 2014-07-22 EP EP14829779.9A patent/EP3024498B1/en active Active
- 2014-07-22 KR KR1020247016862A patent/KR20240090694A/ko active Search and Examination
- 2014-07-22 HU HUE14829779A patent/HUE047996T2/hu unknown
- 2014-07-22 KR KR1020227009734A patent/KR20220041963A/ko not_active Application Discontinuation
- 2014-07-22 WO PCT/US2014/047670 patent/WO2015013313A2/en active Application Filing
- 2014-07-22 US US14/338,200 patent/US9840719B2/en active Active
- 2014-07-22 SG SG11201600518WA patent/SG11201600518WA/en unknown
- 2014-07-22 CN CN201910746995.9A patent/CN110606874B/zh active Active
- 2014-07-22 MY MYPI2016000124A patent/MY175477A/en unknown
-
2016
- 2016-01-17 IL IL243633A patent/IL243633B/en active IP Right Grant
- 2016-01-21 SA SA516370442A patent/SA516370442B1/ar unknown
- 2016-01-21 MX MX2021000128A patent/MX2021000128A/es unknown
- 2016-01-21 ZA ZA2016/00481A patent/ZA201600481B/en unknown
- 2016-01-22 PH PH12016500162A patent/PH12016500162A1/en unknown
- 2016-10-26 HK HK16112291.3A patent/HK1223849A1/zh unknown
-
2017
- 2017-12-06 US US15/834,011 patent/US20180187213A1/en active Pending
-
2019
- 2019-02-20 AU AU2019201182A patent/AU2019201182B2/en active Active
- 2019-03-06 JP JP2019041018A patent/JP7094236B2/ja active Active
- 2019-10-22 IL IL270085A patent/IL270085B/en active IP Right Grant
-
2020
- 2020-07-21 IL IL276192A patent/IL276192B/en unknown
- 2020-10-20 PH PH12020551744A patent/PH12020551744A1/en unknown
-
2021
- 2021-01-19 AU AU2021200310A patent/AU2021200310B2/en active Active
- 2021-12-22 IL IL289249A patent/IL289249A/en unknown
-
2022
- 2022-06-21 JP JP2022099592A patent/JP2022126765A/ja active Pending
-
2024
- 2024-01-01 AU AU2024200001A patent/AU2024200001A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019124473A (ru) | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани | |
JP2019116492A5 (ru) | ||
JP6865167B2 (ja) | ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター | |
ES2703814T3 (es) | Terapia génica para la enfermedad de Fabry | |
JP2024009857A5 (ru) | ||
ES2970216T3 (es) | Constructos de terapia génica para tratar la enfermedad de Wilson | |
HRP20192141T1 (hr) | Genska terapija za retinitis pigmentosa | |
JP6956635B2 (ja) | ウィルソン病及び他の状態の処置に使用するための核酸構築物及び遺伝子治療ベクター | |
CN111727243A (zh) | 用于跨越血-脑屏障递送病毒载体的方法和组合物 | |
US8420372B2 (en) | Porcine adeno-associated viruses | |
JP2017509632A5 (ru) | ||
RU2018119710A (ru) | Кодирующие фактор viii варианты с пониженным содержанием cpg, композиции и способы, и применение в лечении нарушений гемостаза | |
JP2021003120A5 (ru) | ||
RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
CA2907799A1 (en) | Adeno-associated virus variants and methods of use thereof | |
WO2010109053A1 (es) | Métodos y composiciones para el tratamiento de cirrosis y fibrosis hepática | |
JP2018506261A5 (ru) | ||
JP2020519284A5 (ru) | ||
JP2020533276A5 (ru) | ||
ES2824829T3 (es) | Vectores de virus adenoasociado que codifican G6PC modificada y usos de estos | |
JP2017529395A5 (ru) | ||
AR123948A1 (es) | ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES | |
WO2021113634A1 (en) | Transgene cassettes designed to express a human mecp2 gene | |
KR20230135093A (ko) | T-세포를 표적화하는 aav 벡터 | |
RU2018124448A (ru) | Векторы на основе аденоассоциированного вируса для лечения муколипидоза типа ii |